All In Biotech

Drug Trial Radar · NCT04776629

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

77

Actual

Start

Jun 30, 2021

Primary completion

Nov 11, 2022

Study completion Nov 11, 2022

Sponsor

Lead sponsor
AbcentraIndustry
Sponsor type
Industry
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.

Conditions

  • Psoriasis
  • Inflammation
  • Coronary Artery Disease
  • Cardiometabolic Syndrome

Interventions

  • OrticumabDrug

    A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope

  • PlaceboDrug

    Placebo for orticumab, containing all components of formulation except the active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)Time frame: 106 days (Week 15)
  2. Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) ScoreTime frame: 106 days (Week 15)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CCT- Research at the center for Dermatology and Plastic Surgery

    Scottsdale, Arizona

  • Derm Institute & Skin Care Ctr., Inc.

    Santa Monica, California

  • Orange County Research Center

    Tustin, California

  • Blue Coast Research Center

    Vista, California

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Las Vegas Clinical Trials

    Las Vegas, Nevada

  • Excel Clinical Research

    Las Vegas, Nevada

  • Vital Prospects Clinical Research Institute, PC

    Tulsa, Oklahoma

  • SMS Clinical Research

    Mesquite, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Center for Clinical Studies, LTD.LLP

    Webster, Texas

  • CCT Research - Springville Dermatology

    Springville, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.